Bora Pharmaceuticals invests $10M to expand oral solid dose capabilities at two sites
The investment will expand operations over two years at facilities in Taiwan and Canada
Bora Pharmaceuticals has announced plans to invest $10 million to expand its oral solid dose capabilities over two years across facilities in Zhunan, Taiwan and Mississauga, Canada.
The fast-growing contract development and manufacturing organisation (CDMO) provides services including clinical and commercial manufacturing, pharmaceutical development, packaging and serialisation, and analytical/microbiology testing. It has two facilities in Taiwan, located in Tainan and Zhunan, and one in Canada.
Coinciding with the investment, Bora Mississauga relaunched a pilot facility that was purpose-built for development and clinical manufacturing and is separate from its commercial manufacturing activities.
The facility has 25 flexible rooms which include misting showers and a separate air-handling unit to allow for clinical manufacturing of conventional and potent compounds at various batch sizes for oral solid dose as well as liquids, creams and ointments.
The Mississauga site also acquired the Gerties MINI-PACTOR®, a laboratory roller compactor solution, which will be operational in the second quarter of 2022.
In Zhunan, the company is set to commission a development / clinical area purpose built for containment. The space will allow Bora to safely handle High Potent Oral Solid Dose products categorized as OEB Level 4, <0.01 mg/m3. A new blister line will also be added to complement the current tablet and capsule packaging capabilities on site.
Construction in Zhunan is expected to begin in Q2 2022, with operations planned for the first quarter of 2023.
Bora CEO Bobby Sheng said the investments in Zhunan and Mississauga ‘really reinforce our company’s commitment to our facilities’ and are a ‘testament to the teams and talent pools we have there’.
‘We now intend to invest further into our growth strategy and continue to be the best CDMO partner we can be,’ he said.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance